Literature DB >> 12946484

Multiple endocrine neoplasia type 1: duodenopancreatic tumors.

Gerard M Doherty1.   

Abstract

Duodenopancreatic endocrine tumors are the most frequently lethal part of MEN-1. The management of these patients is complicated by the variable hormonal function of the tumors, and the often indolent but occasionally lethal nature of the tumors. This article reviews our current approach to the diagnosis, surveillance and management of these patients.

Entities:  

Mesh:

Year:  2003        PMID: 12946484     DOI: 10.1016/s0960-7404(03)00038-0

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  10 in total

1.  Screening of pancreaticoduodenal endocrine tumours in patients with MEN 1: multidetector-row computed tomography vs. endoscopic ultrasound.

Authors:  L Camera; S Paoletta; C Mollica; F Milone; V Napolitano; L De Luca; A Faggiano; A Colao; M Salvatore
Journal:  Radiol Med       Date:  2011-02-01       Impact factor: 3.469

2.  Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas.

Authors:  Frederic Triponez; David Dosseh; Pierre Goudet; Patrick Cougard; Catherine Bauters; Arnaud Murat; Guillaume Cadiot; Patricia Niccoli-Sire; Jean-Alain Chayvialle; Alain Calender; Charles A G Proye
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

3.  Natural History of MEN1 GEP-NET: Single-Center Experience After a Long Follow-Up.

Authors:  Francesco Giudici; Tiziana Cavalli; Francesca Giusti; Giorgio Gronchi; Giacomo Batignani; Francesco Tonelli; Maria Luisa Brandi
Journal:  World J Surg       Date:  2017-09       Impact factor: 3.352

4.  Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE.

Authors:  Frederic Triponez; Pierre Goudet; David Dosseh; Patrick Cougard; Catherine Bauters; Arnaud Murat; Guillaume Cadiot; Patricia Niccoli-Sire; Alain Calender; Charles A G Proye
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

5.  Preoperative assessment of the pancreas in multiple endocrine neoplasia type 1.

Authors:  Mark A Lewis; Geoffrey B Thompson; William F Young
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

6.  Co-existence of glucagonoma with recurrent insulinoma in a patient with multiple endocrine neoplasia-type 1 (MEN-1).

Authors:  Takamasa Nishiuchi; Hitomi Imachi; Koji Murao; Mako Fujiwara; Tomie Muraoka; Fumi Kikuchi; Yukiko Nishiuchi; Yoshio Kushida; Reiji Haba; Toshihiko Ishida
Journal:  Endocrine       Date:  2009-04-07       Impact factor: 3.633

7.  Neuroendocrine Tumors of the Pancreas.

Authors:  James M. McLoughlin; Joseph A. Kuhn; Jeffrey T. Lamont
Journal:  Curr Treat Options Gastroenterol       Date:  2004-10

8.  Primary hyperparathyroidism in a patient with primary aldosteronism.

Authors:  Barish Sarıakjali; Esma Jamaspishvili; Mehtap Evran; Murat Sert; Tamer Tetiker
Journal:  BMC Res Notes       Date:  2015-07-22

9.  Gastroenteropancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1.

Authors:  Francesco Tonelli; Francesco Giudici; Francesca Giusti; Maria Luisa Brandi
Journal:  Cancers (Basel)       Date:  2012-05-07       Impact factor: 6.639

10.  Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.

Authors:  Tetsuhide Ito; Hisato Igarashi; Hirotsugu Uehara; Marc J Berna; Robert T Jensen
Journal:  Medicine (Baltimore)       Date:  2013-05       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.